Drugs / BI 891065
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04138823 | Nov 2019 → May 2023 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03166631 | Sep 2017 → Sep 2020 | metastatic neoplasm, non-small cell lung carcinoma | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 891065 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03166631 ↗ |
| Action | Inhibit | “cIAP1 levels were reduced in PBMCs and biopsies” PMID 41408891 ↗ Dec 2025 |
| Modality | Other / unclassified | “BI 891065, a second mitochondria-derived activator of caspases mimetic” PMID 41408891 ↗ Dec 2025 |
| Target | BIRC2 | “targets the inhibitor of apoptosis (IAP) family member cIAP1” PMID 41408891 ↗ Dec 2025 |